Trial Outcomes & Findings for Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma (NCT NCT00003472)

Last Updated: 2018-03-21

Results Overview

Objective response rate per Response Assessment in Neuro-Oncology (RANO) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all disease sustained for at least four weeks; Partial Response (PR), \>=50% decrease in the sum of the products of of the greatest perpendicular diameters of all measurable enhancing lesions, sustained for at least four weeks.

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

13 participants

Primary outcome timeframe

12 months

Results posted on

2018-03-21

Participant Flow

Thirteen patients were recruited between May 1996 and August 2007. All study subjects were seen at the Burzynski Clinic in Houston TX

Participant milestones

Participant milestones
Measure	Antineoplaston Therapy Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Overall Study STARTED	13
Overall Study COMPLETED	10
Overall Study NOT COMPLETED	3

Reasons for withdrawal

Reasons for withdrawal
Measure	Antineoplaston Therapy Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Overall Study Not evaluable	3

Baseline Characteristics

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Antineoplaston Therapy n=13 Participants Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Age, Continuous	41.5 Years n=5 Participants
Sex: Female, Male Female	5 Participants n=5 Participants
Sex: Female, Male Male	8 Participants n=5 Participants

PRIMARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure	Antineoplaston Therapy n=10 Participants Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Number of Participants With Objective Response Partial Response	2 Participants
Number of Participants With Objective Response Stable Disease	4 Participants
Number of Participants With Objective Response Progressive Disease	4 Participants

SECONDARY outcome

Timeframe: 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

Population: All study subjects receiving any Antineoplaston therapy

6 months, 12 months, 24 months, 36 months, 48 months, 60 months overall survival

Outcome measures

Outcome measures
Measure	Antineoplaston Therapy n=13 Participants Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Percentage of Participants Who Survived 6 months overall survival	76.9 Percentage of participants
Percentage of Participants Who Survived 12 months overall survival	61.5 Percentage of participants
Percentage of Participants Who Survived 24 months overall survival	46.2 Percentage of participants
Percentage of Participants Who Survived 36 months overall survival	23.1 Percentage of participants
Percentage of Participants Who Survived 48 months overall survival	15.4 Percentage of participants
Percentage of Participants Who Survived 60 months overall survival	7.7 Percentage of participants

Adverse Events

Antineoplaston Therapy

Serious events: 7 serious events

Other events: 13 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Antineoplaston Therapy n=13 participants at risk Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
General disorders Central Venous Catheter: Infection	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Fatigue (asthenia, lethargy, malaise)	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Hemorrhage, CNS	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Blood	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Lung (pneumonia)	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Scrotum	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Soft tissue NOS	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypernatremia	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Musculoskeletal and connective tissue disorders Fracture	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Cognitive disturbance	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Confusion	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Neuropathy: motor	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Seizure	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Somnolence/depressed level of consciousness	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX

Other adverse events

Other adverse events
Measure	Antineoplaston Therapy n=13 participants at risk Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Immune system disorders Allergic reaction/hypersensitivity (including drug fever)	23.1% 3/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Ear and labyrinth disorders Otitis, external ear (non-infectious)	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Ear and labyrinth disorders Tinnitus	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Blood and lymphatic system disorders Hemoglobin	30.8% 4/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Blood and lymphatic system disorders Leukocytes (total WBC)	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Blood and lymphatic system disorders Lymphopenia	30.8% 4/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Blood and lymphatic system disorders Neutrophils/granulocytes (ANC/AGC)	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Blood and lymphatic system disorders Platelets	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Cardiac disorders Hypertension	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Central Venous Catheter: Infection	30.8% 4/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Central Venous Catheter: Non-functional	23.1% 3/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Central Venous Catheter: Pain	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Central Venous Catheter: Thrombosis/embolism	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Fatigue (asthenia, lethargy, malaise)	76.9% 10/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Fever	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Weight gain	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Skin and subcutaneous tissue disorders Rash/desquamation	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Skin and subcutaneous tissue disorders Rash: acne/acneiform	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Edema/Fluid retention	46.2% 6/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Constipation	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Diarrhea	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Heartburn/dyspepsia	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Mucositis/stomatitis (clinical exam): Oral cavity	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Nausea	38.5% 5/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Vomiting	30.8% 4/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Hemorrhage, CNS	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Renal and urinary disorders Hemorrhage, GU: Bladder	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection - Other	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Bladder (urinary)	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Blood	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Lung (pneumonia)	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Middle ear (otitis)	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Mucosa	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Scrotum	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Soft tissue NOS	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Upper airway NOS	30.8% 4/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Urinary tract NOS	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Opportunistic infection	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Albumin, serum-low (hypoalbuminemia)	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Alkaline phosphatase	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations GGT (gamma-Glutamyl transpeptidase)	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypercholesteremia	23.1% 3/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hyperglycemia	23.1% 3/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypernatremia	46.2% 6/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypocalcemia	30.8% 4/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypoglycemia	23.1% 3/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypokalemia	84.6% 11/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypophosphatemia	23.1% 3/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Proteinuria	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations SGOT	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations SGPT	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Uric acid, serum-high (hyperuricemia)	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Musculoskeletal and connective tissue disorders Fracture	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Ataxia (incoordination)	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Cognitive disturbance	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Confusion	38.5% 5/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Dizziness	38.5% 5/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Mood alteration: Agitation	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Neurology - Other	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Pyramidal tract dysfunction	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Seizure	30.8% 4/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Somnolence/depressed level of consciousness	46.2% 6/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Speech impairment	23.1% 3/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Neuropathy: motor	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Eye disorders Ocular/Visual - Other	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Pain: Abdomen NOS	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Renal and urinary disorders Pain: Bladder	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Endocrine disorders Pain: Breast	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Musculoskeletal and connective tissue disorders Pain: Chest wall	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Pain: Head/headache	61.5% 8/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Musculoskeletal and connective tissue disorders Pain: Joint	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Musculoskeletal and connective tissue disorders Pain: Muscle	23.1% 3/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Musculoskeletal and connective tissue disorders Pain: Neck	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Respiratory, thoracic and mediastinal disorders Pain: Throat/pharynx/larynx	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Respiratory, thoracic and mediastinal disorders Dyspnea (shortness of breath)	7.7% 1/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX
Renal and urinary disorders Urinary frequency/urgency	15.4% 2/13 • 11 years, 4 months Thirteen patients were recruited between May 1996 and September 2007. All study subjects were seen at the Burzynski Clinic in Houston TX

Additional Information

S. R. Burzynski, MD, PhD

Burzynski Research Institute, Inc.

Phone: 713-335-5664

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place